BURBANK, Calif., Dec. 08, 2016 (GLOBE NEWSWIRE) -- Imaging3, Inc. (OTCQB:IGNG) announced today that the United
States Supreme Court denied John M. Vuksich’s petition for a rehearing of an order denying a petition for a writ of certiorari in
connection with the Supreme Court’s denial of Vuksich’s previous petition for a writ of certiorari.
In April 2016, Vuksich appealed to the Supreme Court for a writ of certiorari on the Ninth Circuit rulings that would dismiss
all of his appeals of holdings against him in his various actions against Imaging3. On October 3, 2016, the Supreme Court denied
Vuksich’s application.
On October 25, 2016, Vuksich filed a petition for a rehearing of the order denying a petition for a writ of certiorari. On
December 6, 2016, The Supreme Court denied this petition. As a result, the Vuksich litigation against Imaging3 is now definitively
terminated.
About Imaging3
Imaging3, Inc., founded in 1993, has developed a patented medical imaging technology, called SmartScan™, that will produce 3D
medical images in virtual real time. The SmartScan technology will allow healthcare professionals to perform diagnostic and
therapeutic procedures more quickly and accurately, with fewer safety risks for the patient. In addition, Imaging3’s technology
exposes patients to significantly less harmful radiation than current imaging technologies such as CT scans, which the company
believes will allow scans to be used in more pediatric applications than are currently prescribed. The technology also allows for
greater portability, easier installation, and a significantly reduced cost burden for the healthcare system overall. Imaging3 is
planning to submit a 510K application to the FDA during 2017 in order to gain approval to commercialize the SmartScan
technology.
Visit the company’s website at http://www.imaging3.com for detailed information about the Company’s technology.
Safe Harbor Statement
Imaging3 cautions you that any statement included in this press release that is not a description of historical facts is a
forward-looking statement. Many of these forward-looking statements contain the words "anticipate," "believe," "estimate," "may"
"intend," "expect" and similar expressions. Actual results, performance or achievements could differ materially from those
contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based
largely on the expectations of the company and are subject to a number of risks and uncertainties inherent in the Imaging3’s
business, including, without limitation: the company may not ever obtain FDA approval for any of its devices; the company may
not be able to secure the funds necessary to support its product development plans; and the company may not ever achieve the market
success to sustain a profitable business. In addition, there are risks and uncertainties related to economic recession or
terrorist actions, competition from much larger imaging companies, technological obsolescence, unexpected costs and delays,
potential product liability claims, and many other factors. More detailed information about Imaging3 and the risk factors that may
affect the realization of forward-looking statements is set forth in the company’s filings with the Securities and Exchange
Commission, including the company’s Annual Report on Form 10-K and its Quarterly Report on Form 10-Q. Such documents may be
read free of charge on the SEC’s website at www.sec.gov. You are cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary
statement, and Imaging3 undertakes no obligation to revise or update this press release to reflect events or circumstances after
the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation
Reform Act of 1995.
Investor Relations Contact: Amato and Partners, LLC 90 Park Avenue, 17th Floor New York, NY 10016 admin@amatoandpartners.com
